ANAB
AnaptysBio, Inc.
There isn't enough reported data to score ANAB yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
ANAB Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Strong |
ANAB's balance sheet is currently strong, but its profitability is under pressure. There isn't enough data to rate its revenue and cash flow.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
ANAB PE Valuation
ANAB has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 5.3x next year's earnings.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
ANAB Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect ANAB to return to profit, with revenue growing. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
ANAB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $9.01 | — |
| Q1 2026 | -$1.02 | +$3.74 |
| Q4 2025 | -$0.46 | +$4.66 |
| Q3 2025 | -$2.73 | +$3.35 |
| Q2 2025 | -$4.39 | +$1.96 |
| Q1 2025 | -$4.76 | +$1.38 |
| Q4 2024 | -$5.12 | +$0.96 |
| Q3 2024 | -$6.08 | -$0.66 |
| Q2 2024 | -$6.35 | -$1.16 |
OSCR has the stronger earnings trend. Trailing diluted EPS is down 121% for ANAB versus OSCR up 147%.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
ANAB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $30.3M | -60% |
| Q1 2026 | $25.6M | -8% |
| Q4 2025 | $108.2M | +151% |
| Q3 2025 | $76.3M | +154% |
| Q2 2025 | $22.3M | +103% |
| Q1 2025 | $27.8M | +287% |
| Q4 2024 | $43.1M | +379% |
| Q3 2024 | $30M | +805% |
OSCR has the stronger quarterly revenue trend. Revenue is up 36% for ANAB versus up 72% for OSCR.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 66% | +20 points |
| Q1 2026 | -136% | -36 points |
| Q4 2025 | 62% | +84 points |
| Q3 2025 | 45% | +121 points |
| Q2 2025 | -118% | +250 points |
| Q1 2025 | -99% | +489 points |
| Q4 2024 | -22% | +446 points |
| Q3 2024 | -76% | +1061 points |
ANAB has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR's revenue has grown year over year every quarter since early 2021: $5.1B last quarter, up 72% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
ANAB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$9.5M | +$17.8M |
| Q1 2026 | -$25.9M | -$15.2M |
| Q4 2025 | $98M | +$164.9M |
| Q3 2025 | -$27.4M | -$17.2M |
| Q2 2025 | -$40.3M | -$18.9M |
| Q1 2025 | -$10.7M | +$26.5M |
| Q4 2024 | -$66.9M | -$32.3M |
| Q3 2024 | -$10.1M | +$26.5M |
OSCR has the stronger cash trend. Its trailing FCF is up 545% versus its history, compared with ANAB at up 149%.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
ANAB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +22% | +6.4M shares |
| 1 year | +22% | +6.3M shares |
| 3 years | +32% | +8.4M shares |
| 5 years | +28% | +7.7M shares |
| Available history | +30% | +8M shares |
ANAB has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q1 2026 | — |
| Q4 2025 | $3.4M |
| Q3 2025 | $9.7M |
| Q2 2025 | $51.1M |
| Q1 2025 | $4.4M |
| Q4 2024 | $456,000 |
| Q3 2024 | — |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
ANAB Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -6.0x | Net Cash |
| Q4 2025 | -4.9x | Net Cash |
| Q3 2021 | -40.6x | Net Cash |
ANAB has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
ANAB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.4 | Neutral |
| Stochastic | 21.4 | Neutral |
ANAB's weekly RSI is 45 (neutral) and its Stochastic is 21 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
ANAB PE vs Healthcare Sector
| Metric | ANAB | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ANAB has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
ANAB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $47.9 | 0.3% below |
| 20 week MA | $53.7 | 11% below |
| 50 week MA | $47.7 | 0.1% above |
| 100 week MA | $31.5 | 52% above |
| 200 week MA | $23.5 | 103% above |
ANAB has pulled back, but its long-term trend is still up: it's below its 8- and 20-week averages, but 103% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over ANAB on trend strength, trading above more of its moving averages.
ANAB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $11.2 | $14.8 | +33% |
| 2021 | $14.8 | $24.7 | +67% |
| 2022 | $24.7 | $19.5 | -21% |
| 2023 | $19.5 | $14.3 | -27% |
| 2024 | $14.3 | $8.69 | -39% |
| 2025 | $8.69 | $33.4 | +284% |
| 2026 YTD | $33.4 | $47.8 | +43% |
ANAB is up 43% so far in 2026, after finishing lower in three of the previous six years.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over ANAB on returns for 2026, with the stronger performance.